Microbix Clot-Buster Drug Fully-Funded for Return to U.S. Market

Microbix Biosystems Inc., a life sciences innovator, manufacturer and exporter, recently announced the reconfirmation of its agreement with Sequel Pharma, LLC to return Kinlytic® urokinase to market in the United States, followed by other geographies and clinical indications. Kinlytic is an enzyme derived from human cell cultures that dissolves the material of a blood clot. A further payment of US$ 2.0 million has been received by Microbix relating to this reconfirmation.

Microbix is an OBIO® member and an alumnus of the BDSP™ and H2BB™ programs.